CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss	$ (69,609)	$ (55,339)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,926	3,559
Equity-based compensation	11,162	12,643
Change in fair value of warranty liability	19,523	9,800
Change in fair value of asset purchase agreement liability	(2,217)
Realized and unrealized gain on short term investments	(517)	(501)
Equity method investment loss	118	157
Asset retirement obligation accretion	51	51
Amortization of debt discount	4,526	1,771
Changes in operating assets and liabilities:
Accounts receivable	97	(569)
Other current assets	269	1,246
Other assets	60	84
Accounts payable	527	(102)
Deferred revenue	6	(23)
Accrued expenses and other liabilities	5,144	2,140
Operating lease right-of-use assets and liabilities	874	476
Net cash used in operating activities	(26,060)	(24,607)
Investing activities
Capitalization of costs and purchases of network assets, property, and equipment	(182)	(2,541)
Purchase of internal use software	(354)	(708)
Purchase of marketable securities	(44,894)	(33,494)
Sale and maturity of marketable securities	30,500	35,249
Payment for asset purchase agreement liability	(2,732)
Net cash used in investing activities	(17,662)	(1,494)
Financing activities
Proceeds from senior secured notes		70,000
Payments towards debt issuance cost		(1,861)
Payments towards debt	(82)	(82)
Proceeds from exercise of common warrants	27,896	882
Redemption of non-controlling interests	40
Proceeds from exercise of common stock options	1,882	66
Net cash provided by financing activities	29,736	69,005
Effect of exchange rates on cash and cash equivalents	13	(2)
Net (decrease) increase in cash and cash equivalents	(13,973)	42,902
Cash and cash equivalents at beginning of period	81,878	47,230
Cash and cash equivalents at end of period	67,905	90,132
Non-cash investing and financing information
Capital expenditure included in Accrued expenses and other current liabilities	159	120
Issuance of warrants		22,843
Interest paid in shares of Common Stock	$ 1,867